Artificial Vital Organs and Medical Bionics Market is Predicted to See Lucrative Gains Over 2021-2022
By 2022, the global market for artificial vital organs and medical bionics is predicted to have grown to USD 45.92 billion. Over the forecast period, the rising prevalence of disorders such as respiratory ailments, cirrhosis, heart, and kidney and liver failures are expected to raise demand for synthetic organs. Furthermore, the unprecedented growth of the senior population, which is especially susceptible to organ ailments, contributes significantly to the artificial vital organs and medical bionics industry.
Over the
forecast period, technological breakthroughs about a novel product
development, such as SynCardia Systems Inc.'s full-functioning artificial heart
that caters to the needs of organ recipients, are likely to fuel the artificial
vital organs and medical bionics market growth.
Additionally,
shortage of organs and tissues for transplantation, rising need for
immunosuppressive medications, and increased R&D procedures for organ
regeneration through modified tissues is likely to boost market expansion.
Furthermore,
positive government initiatives to maintain patient safety standards are
predicted to support artificial vital organs and the medical bionics market
expansion over the forecast period, which is expected to help artificial vital organs and medical bionics market growth.
Over the
forecast period, improvements in the durability and compatibility of organ
implants, as well as targeted research on reducing complication rates, are
expected to fuel artificial market growth. Over the forecast period, market
growth is expected to be aided by the introduction of life-saving technologies
such as the bridge to transplant and the bridge to recovery in critical instances.
The
artificial vital organs category, which accounted for almost 64% of the market,
is predicted to increase at a CAGR of 7.7% while maintaining its dominance
during the forecast period. Rapid technical breakthroughs and a large number of
unmet needs are two major drivers driving market expansion. Furthermore,
increased patient acceptability is envisaged as medical bionics become more
well-known.
Because of
the increasing acceptance of artificial organs in emerging economies, North
America was designated as the largest regional sector in 2014, with a market
share of about 42 percent. Furthermore, with a low rate of cadaveric organ
donation, artificial organ transplants are projected to become more common. In
addition, the region's economy is predicted to be groomed during the forecast
period due to the large presence of key businesses operating in the region and
the growing capacity of healthcare expenditure. During the projected period,
Europe, followed by the Asia Pacific, is expected to have the biggest gain in
revenue share.
The leading
companies in the industry include Medtronic Inc., Baxter International, Edwards
LifeScience Corporation, Touch Bionics, WorldHeart Corporation, and Abiomed
Inc. These companies create a wide range of goods to meet the needs of a wide
range of surgical applications, including cardiovascular problems and organ
failures.

Comments
Post a Comment